Loading page
Loading page
Loading substance route
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Zolpidem misuse has been associated with dependence and addiction, often driven by its euphoric effects. A 2014 review found evidence of drug-seeking behavior, with zolpidem prescriptions making up 20% of falsified or forged prescriptions. Recreational use is more prevalent in those with a history of drug dependence, though addiction can develop in individuals without such history.
Physical dependence develops with prolonged use, producing withdrawal symptoms resembling benzodiazepine withdrawal. Abrupt discontinuation may cause tremors, delirium, irritability, and in severe cases, seizures. Reported cases of high-dose dependence document daily doses up to 6,000 mg, with tapering or benzodiazepine substitution typically required for discontinuation.
Overdose can lead to impairment of consciousness ranging from somnolence to light coma, cardiorespiratory collapse, and fatal outcomes. Zolpidem overdose can be treated with the GABA-A receptor antagonist flumazenil.
| Species | Route | Value |
|---|---|---|
| rat | oral | 695 mg/kg |
CNS depressant effects including somnolence, respiratory depression, and impaired consciousness occur during intoxication; organ toxicity is rare even at high doses, though severe CNS effects can occur with overdose or extreme use.
Anterograde amnesia may occur, particularly at doses above 10 mg; a marked reduction in next-morning recall of information relayed during peak drug effect has been observed in controlled studies.
Two-year animal studies showed no evidence of carcinogenicity in mice; renal tumors observed in rats were attributed to spontaneous occurrence. Zolpidem showed no mutagenic activity in multiple genotoxicity assays. However, a 2017 meta-analysis of epidemiological studies found zolpidem use associated with a 34% increased cancer risk, though results were tentative due to confounding factors including smoking and alcohol use.
Hallucinations through multiple senses and delusions are reported, particularly at higher doses. Complex sleep behaviors with amnesia are well-documented. Delirium may occur during withdrawal from chronic use. Visual hallucinations have been noted more frequently when zolpidem is combined with antidepressants.
Seizures are primarily a withdrawal risk rather than an acute effect. Abrupt discontinuation after prolonged use or high doses may cause seizures, particularly in chronic users who have developed physical dependence. Gradual dose reduction is recommended to minimize this risk.
Zolpidem entered clinical use in Europe in 1988 through the pharmaceutical company Synthelabo. Following its European introduction, Synthelabo collaborated with Searle to pursue regulatory approval in the United States. The FDA granted approval in 1992, and the drug was marketed under the brand…
12 sources cited